I hear you! Good luck. Your patience and resiliency is definitely being tested and will continue to be tested. Personally, I think there are better places in the biopharma space to put your money. If you like investing a long side big names, take a look at ZIOP. They are backed by one of the all time greatest biopharma investor.
Again, good luck to you....
I agree. The shares are an absolute steal at these prices. They have great Management, biomedical technology, and they have the funding albeit not using the best firm. It's just a matter of time now:).
Sol Barer and Isaac Blech would not be involved if Medgenics was not a safe bet as there are plenty of bio firms that wuld love to have their support. There is a reason they have invested time and money in Medgenics unique delivery and protein production platform. It is a game changer and given time and money, MDGN will be huge. Patience and resiliency will prove this to be a winner. Don't take your eyes off the prize as short term dilutions and fund raise detour the stock prices. Time will tell who is right !
Sentiment: Strong Buy
Stop chasing dog poop! Look at KERX, CYTK, REGN, QCOR, THRX and RIGL if you want to play biopharma. MDGN is dead!!!! Look at my posts from last year. The lack capital and the dilution is going to be enormous to existing shareholders. Stay away!!!! THRX has plenty more to go.....REGN is way ahead of itself now but a great long term play!!!! See my posts! I've been in it for 5-years!!!! QCOR is an excellent value leverage play. It just started to breakout recently again. KERX already got good news this year but the best is yet to come. It will be a big time winner over the next 2 - 4 years!!! CYTK and RIGL are much more speculative but are working on some interesting stuff.
Slow and steady! Good luck to all!
Thanks green-side ,
Your comments make sense and should be considered by all who own MDGN. I have owned MDGN since last June then added more. My average is 8 , bummer, but I still like this biotech. I do believe that their science is worthy and will be ground breaking when in a more advanced stage. I would love to add more,when I can, but I still believe that,even if I can't , at some point my investment will more than double.
Good luck all.
Sentiment: Strong Buy
Stocks like MDGN are getting crushed in this stock market. Investors are buying dividend stocks. Story stocks like MDGN are not being bought...hence the low volume. This is when you add. MDGN reported solid Phase IIa results and expanded the number of indications for its biopump in the last month....all good news. Management and its investment banker really messed up back in 2012 by not doing an "at-the-money" stock offering. They were ill prepared. But, have since added a major financier to the Board, so that should help in terms of being smarter raising capital going forward.
I bought this company/s stock for the long term.It had been up over $12 at one time and has come down to $4.00 which I feel is a good entry point.I usually give a small biotech company 3 years to show me how god it can be.Anything shorter is pure speculation not investing.I wish I was good enough to always pick stocks that are about to skyrocket in price,but alas I am not.So my theory is buy low and hold.Then sell higher down the road.I have lots of patience.
Sentiment: Strong Buy
Best to do your own DD and be comfortable with where you invest. I'm interested in their technology, Sol apparently is too. They have had past missteps, but he is on board, has raised capitol, and their lead product candidate is showing positive indications. Still miles to go, but thats what makes for the big winners. Good Fortune
could you give me a quick run down on mdgn? thanks, why is it trading here?
eman is going to rock hard on friday! go eman
I see what you are referring to, not sure why it is filled/classified this way. Maybe it's just how the stock compensation change gets classified? Don't think this is anything major, just a typical authorization to grant compensation shares.
Congrats on the CELG success. Been watching MDGN for a long time, before Sol showed up. Have also been in situation where I bought early and had to wait/ride one back up. Looked to me like it had bottomed and started back up, so began adding at $4.08. I have learned to be patient with biotech, as long as I believe in the team. I like Sol's track recored and expect he wants to win again. Don't know for sure, but have taken a position and will continue to learn and add as appropriate. Good Fortune!
I sure hope this company succeeds. (Side from my retirement funds) I have officially broken the rules and have a majority of my eggs in this basket. With the PPS being so low, I have an average buy price of $6.40/share. Eager for a spike.......
I unfortunately bought 2000 shares of MDGN at about 11 dollars, because Sol Barer had joined the board, and I've done rather well with my 7K shares of Celgene. Unfortunately, not so well with MDGN. I read through th SEC 8K document about a change in directors. I don't see anything in the document that says there is a change in directors. I just see that the company authorized another 1.7 million shares. So am I missing somethin regarding the "very interesting news." And is the news good or bad?
If interested in more background, you can Google an article titled, "Medgenics: Former CEO Of Celgene Believes In His Newest Biotech Venture".
Today seems like profit taking for those who bought below or around $4 but I do expect the PPS to slowly rise over the following days, hopefully we can get much closer to $5
Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients on dialysis with end-stage renal disease (“ESRD”).
observations from the Company’s prior Phase I/II study in anemic pre-dialysis patients.
Hemoglobin in these patients remained in the desired 9-11 g/dl range for approximately 2-4 months, without needing any EPO or other ESA injections. Notably, at no point following EPODURE treatment did the concentration of EPO in the serum of the patients exceed the typical normal range and always remained under 100 mU/ml.
well aapl is down 40 perecent from it's high, not from an "offering" price of a secondary they floated (like mdgn)...and still, one co. has nothiing to do with the other....mdgn fell because of dilution; aapl is down because of lowered earning expectations....so i really don't see any comparison
I own some AAPL and it is down 40%.So what is good for AAPL is good for MDGN also.Is that logical? Actually I was looking for a 30-40% drop from the $5.25 dilution price which sometimes happens when fear takes hold of investors.I actually was just looking for something below $4.00 when it started to fall in price dramatically.
Sentiment: Strong Buy